Emergent BioSolutions Secures $34.5M Deal to Manufacture JE Vaccine and Distribute to U.S. Government
Emergent BioSolutions agreed to a $34.5 million manufacturing services deal with Substipharm Biologics to produce Japanese Encephalitis vaccine substance at its Canton, Massachusetts, BSL-2 facility with 'No Action Indicated' FDA status. The company will scale up production, hire additional staff and gain exclusive U.S. government distribution rights upon approval.
1. Strategic Manufacturing Partnership
Emergent BioSolutions entered a $34.5 million master Manufacturing Services Agreement with Substipharm Biologics to produce drug substance for the IMOJEV Japanese Encephalitis vaccine at its Canton, Massachusetts facility, and will serve as the exclusive distributor to the U.S. government pending FDA approval.
2. Canton Facility Compliance and Scale-Up
The Canton site, a multi-product BSL-2 commercial facility, received a 'No Action Indicated' classification after a February 2026 FDA inspection, validating its cGMP compliance. Emergent has initiated scale-up efforts at the facility and plans to hire additional staff later this year.
3. Future Commercialization and Government Supply
Under the distribution agreement, Emergent will manage U.S. government supply of the JE vaccine upon regulatory approval and maintain international product inventory. This partnership supports onshoring of critical biologics and positions Emergent for future strategic collaborations.